With Biohaven deal, SK Biopharma builds epilepsy franchise, takes step toward ‘big biotech’

A deal with Biohaven will give Korean company SK Biopharma another program for its global epilepsy franchise behind Xcopri, its partial-onset seizure drug and primary growth engine.

SK Biopharmaceuticals Co. Ltd. (KRX:326030) is paying Biohaven Ltd. (NASDAQ:BHVN) $350 million up front for an exclusive, worldwide license to opakalim (BHV-7000), as well as the potassium channel Kv7 platform from which it was developed...